



Oncology Research International Limited
ACN 067 964 621

Continuous Disclosure

October 2013

1. POLICY

- 1.1. Oncology Research International Limited (the Company) is committed to ensuring that the market and shareholders are provided with complete and timely information on the Company.
- 1.2. The Company is also committed to complying with the continuous disclosure requirements arising from legislation.
- 1.3. The general rule, in accordance with the continuous disclosure requirements, is that once the Company becomes aware of any information concerning it that a reasonable person would expect to have a material effect on the price or value of the Company's shares, the Company must immediately disclose that information.
- 1.4. The Company has in place a written policy on information disclosure and relevant procedures.
- 1.5. The focus of these procedures is on continuous disclosure compliance and improving access to information for investors.
- 1.6. The Company Secretary is responsible for:
 - 1.6.1. overseeing and co-ordinating disclosure of information to the Australian Securities and Investments Commission (ASIC) and shareholders; and
 - 1.6.2. providing guidance to Directors and employees on disclosure requirements and procedures.
- 1.7. All information that is expected to have a material effect on the price or value of the Company's shares is posted on the Company's website with the aim of making the information readily accessible to the widest audience as soon as practicable.